A new diabetes vaccine approach shows promise by selectively neutralizing antigens while leaving the rest of the immune system unaffected.
A phase 2 study of the vaccine product (TOL-3021) has yielded some impressive findings.
John Schieszer has the latest on the story in today’s Medical Minute.
Next post in The Medical Minute
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.